Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib

Clinical Cancer Research

Volumn 18, Issue 18, 2012, Pages 4997-5007

  Lachenmayer, Anja ^a,b   Alsinet, Clara ^a,c   Savic, Radoslav ^a   Cabellos, Laia ^a   Toffanin, Sara ^a,e   Hoshida, Yujin ^f   Villanueva, Augusto ^c   Minguez, Beatriz ^a   Newell, Philippa ^a,g   Tsai, Hung Wen ^a   Barretina, Jordi ^f   Thung, Swan ^a   Ward, Stephen C ^a   Bruix, Jordi ^c   Mazzaferro, Vincenzo ^e   Schwartz, Myron ^a   Friedman, Scott L ^a   Llovet, Josep M ^a,c,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c UNIVERSITY OF BARCELONA   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^g PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; GLUTAMATE SYNTHASE; MESSENGER RNA; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CTNNB1 GENE; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME REGULATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; REPRODUCIBILITY OF RESULTS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84866532501     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2322     Document Type: Article

References (37)

1. Jemal A, Bray F, CenterMM,Ferlay J, Ward E, FormanD. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
3. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010;30:35-51.
4. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008;8:387-98.
5. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007;45:42-52.
6. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008;68:6779-88.
7. Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, et al. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011;140:1618-28.
8. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009;69: 7385-92.
9. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008;68:1451-61.
10. Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 2007;67:10831- 9.
11. Hoppler S, Kavanagh CL. Wnt signalling: variety at the core. J Cell Sci 2007;120:385-93.
12. Hoshida Y. Nearest template prediction: a single-sample-based flexible class prediction with confi dence assessment. PLoS One 2010;5: e15543.
13. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. Gene- Pattern 2.0. Nat Genet 2006;38:500-1.
14. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990;9:811- 8.
15. Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, et al. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin Cancer Res 2011;17:2591-601.
16. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996;6:1664-8.
17. Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006;131:1758-67.
18. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972-83, 83 e1-11.
19. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000;28:27- 30.
20. Bengochea A, de Souza MM, Lefrancois L, Le Roux E, Galy O, Chemin I, et al. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer 2008;99:143-50.
21. Merle P, De La Monte S, Kim M, Herrmann M, Tanaka S, Von dem Bussche A, et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 2004;127:1110-22.
22. Ravindranath A, Yuen HF, Chan KK, Grills C, Fennell DA, Lappin TR, et al. Wnt-beta-catenin-Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer. Br J Cancer 2011;105:542-51.
23. Bonnans C, Flaceliere M, Grillet F, Dantec C, Desvignes JP, Pannequin J, et al. Essential requirement for beta-arrestin2 in mouse intestinal tumors with elevated Wnt signaling. Proc Natl Acad Sci U S A 2012;109:3047-52.
24. Saitoh T, Katoh M. FRAT1 and FRAT2, clustered in human chromosome 10q24.1 region, are upregulated in gastric cancer. Int J Oncol 2001;19:311-5.
25. Saitoh T, Moriwaki J, Koike J, Takagi A, Miwa T, Shiokawa K, et al. Molecular cloning and characterization of FRAT2, encoding a positive regulator of the WNT signaling pathway. Biochem Biophys Res Commun 2001;281:815-20.
26. Zucman-Rossi J, Benhamouche S, Godard C, Boyault S, Grimber G, BalabaudC, et al. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 2007;26:774-80.
27. Yuzugullu H, Benhaj K, Ozturk N, Senturk S, Celik E, Toylu A, et al. Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer 2009;8:90.
28. Cagatay T, Ozturk M. P53 mutation as a source of aberrant betacatenin accumulation in cancer cells. Oncogene 2002;21:7971- 80.
29. Nejak-Bowen KN, Monga SP. Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol 2011;21:44-58.
30. Zhao DH, Hong JJ, Guo SY, Yang RL, Yuan J, Wen CY, et al. Aberrant expression and function of TCF4 in the proliferation of hepatocellular carcinoma cell line BEL-7402. Cell Res 2004;14:74 -80.
31. Burke ZD, Reed KR, Phesse TJ, Sansom OJ, Clarke AR, Tosh D. Liver zonation occurs through a beta-catenin-dependent, c-Myc-independent mechanism. Gastroenterology 2009;136:2316-24 e1-3.
32. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008;47:1955 -63.
33. Khan Z, Vijayakumar S, de la Torre TV, Rotolo S, Bafico A. Analysis of endogenous LRP6 function reveals a novel feedback mechanism by which Wnt negatively regulates its receptor. Mol Cell Biol 2007; 27:7291-301.
34. Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa Cunha A, et al. Hepatocellular adenoma subtype classi fication using molecular markers and immunohistochemistry. Hepatology 2007; 46:740-8.
35. Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 2010;11:1943-55.
36. Han L, Yang Y, Yue X, Huang K, Liu X, Pu P, et al. Inactivation of PI3K/ AKT signaling inhibits glioma cell growth through modulation of beta-catenin- mediated transcription. Brain Res 2010;1366:9- 17.
37. Chai H, Luo AZ, Weerasinghe P, Brown RE. Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line. Int J Clin Exp Pathol 2010;3:408-15.